drugset / Trial / NCT05389046
Study on the Optimal Diagnosis and Treatment Strategy of Major Depressive Disorder Based on Anhedonia
RandomizedParallel-groupSingle-blindTreatment
Summary
This study is a multicenter clinical research and focuses on the exploring of optimal diagnosis and treatment strategies of MDD based on anhedonia.
Timeline
- Start
- 2022-08-15
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aripiprazole | Other / unclassified | 2.5 mg | — |
| Subject | Aripiprazole | Other / unclassified | 10 mg | — |
| Subject | Escitalopram | Small molecule | 10 mg | — |
| Subject | Escitalopram | Small molecule | 20 mg | — |
| Subject | Omega-3 fatty acids | Unknown | 300 mg | — |
| Subject | Omega-3 fatty acids | Unknown | 900 mg | — |
Indications
No indication recorded.